Why did Glenmark Pharmaceuticals (GLENMARK) stock move recently?

On 7/29/2026, Glenmark Pharmaceuticals moved +3.5% — Glenmark's US subsidiary launched Sugammadex Injection (generic) single-dose vials in the US market, a product with ~$1.6B in annual sales, per the July 28 BSE press release. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Glenmark Pharmaceuticals (GLENMARK) overvalued or fairly valued?

MarketChacha shows Glenmark Pharmaceuticals's valuation in context — a forward P/E of about 22.8, a price-to-book of about 5.9 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Glenmark Pharmaceuticals's revenue?

Glenmark Pharmaceuticals reported revenue of ₹8,440 Cr for FY2026, with net profit of ₹-201 Cr, per official filings.

What is the share price of Glenmark Pharmaceuticals (GLENMARK)?

Glenmark Pharmaceuticals last traded at ₹2,210.20 (-0.7% on the day), as of 10/19/2026 — a delayed quote shown for education, not investment advice.

Glenmark Pharmaceuticals

GLENMARK · NSE · Pharma · India

Snapshot

TickerGLENMARK

ExchangeNSE

SectorPharma

IndustryDrug Manufacturers - Specialty & Generic

CountryIndia

Employees16,946

HeadquartersMumbai, India

Websiteglenmarkpharma.com

Filings tracked11

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Limited, together with its subsidiaries, research, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides various products in the therapeutic areas of dermatology, respiratory, oncology, cardiology, diabetes, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, and respiratory-metered dose inhaler, dry powder inhaler, and nasal sprays. Its product pipeline includes ISB 2001, a CD38 x BCMA x CD3 trispecific T cell engager, which is in Phase 1 clinical trial for indication of multiple myeloma; ISB 2301, a Multispecific Immune Cell Activator that is in preclinical trial for solid tumors; ISB 2302, a bispecific immune modulator with an indication for hematologic and solid tumors; and ISB 2501, a trispecific T-cell engager indicated for solid tumors. The company's pipeline also comprises ISB 880, an IL-1RAP antagonist monoclonal antibody, which is in Phase 2 clinical trial for the treatment of hidradenitis suppurativa; and telazorlimab and ISB 830-X8, a OX40 antagonist mAb for the treatment of atopic dermatitis. In addition, the company offers Ryaltris, fixed-dose nasal spray for the treatment of allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.

Who owns it

Promoters49.0%
Institutions27.0%
Public & other24.1%

117 institutional holders

Ownership breakdown from public market data. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend2.3% → 8.0%

Margin has expanded by about 5.7 points — the business is getting more profitable.

Growth qualityrev 7% · PAT 46%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next fiscal year

Rev ₹18,731 Cr · EPS 97.00

Est. earnings growth +23.1%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 5

Revenue (FY2026)

₹16,983 Cr

Net margin

8.0%

Revenue CAGR (3y)

+9.3%

Profit CAGR (3y)

+66.1%

Net profit (FY2026)

₹1,362 Cr

Ask MarketChacha about GLENMARK

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Jul 29, 2026
Glenmark's US subsidiary launched Sugammadex Injection (generic) single-dose vials in the US market, a product with ~$1.6B in annual sales, per the July 28 BSE press release.
source 1 ↗source 2 ↗· confidence: medium

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹16,983 Cr	₹1,362 Cr	8.0%
FY2025	₹13,322 Cr	₹1,047 Cr	7.9%
FY2024	₹11,813 Cr	₹-1,502 Cr	-12.7%
FY2023	₹12,990 Cr	₹297 Cr	2.3%

Quarterly

Period	Revenue	Net profit	Net margin
Q1 FY27	₹4,018 Cr	₹483 Cr	12.0%
Q4 FY26	₹3,771 Cr	₹301 Cr	8.0%
Q3 FY26	₹3,901 Cr	₹403 Cr	10.3%
Q2 FY26	₹6,047 Cr	₹610 Cr	10.1%
Q1 FY26	₹3,264 Cr	₹47 Cr	1.4%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

Filings & announcements

2026

Press Release / Media Release
Glenmark Pharmaceuticals receives Establishment Inspection Report (EIS) from U.S. FDA for its Goa facility with VAI classification
BSE9/23/2026
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Report of Scrutinizer is enclosed
BSE9/11/2026material
Shareholder Meeting / Postal Ballot-Outcome of AGM
Proceedings of the 48th AGM of the Company is enclosed
BSE9/11/2026material
Press Release / Media Release
Glenmark Pharmaceuticals Inc., USA launches Calcium Gluconate Injection USP, 1,000 mg/10 mL (100 mg/mL), 5,000 mg/50 mL (100 mg/mL) Single-Dose Vials and 10,000 mg/100 mL (100 mg/mL) Pharmacy ....
BSE8/21/2026
Press Release / Media Release
Glenmark Pharmaceuticals receives U.S. FDA approval for Fluticasone Propionate Nasal Spray, 0.05 mg (50 mcg)/spray
BSE8/20/2026
Letter To Shareholders Whose Email Address Are Not Registered Providing The Web Link Of Annual Report
Letter to Shareholders whose email address are not registered providing the web link of Annual Report
BSE8/13/2026
Business Responsibility and Sustainability Reporting (BRSR)
Please find attached Business Responsibility and Sustainability Reporting for Financial Year 2025-26
BSE8/13/2026
Reg. 34 (1) Annual Report.
Please find attached Notice convening the 48th Annual General Meeting and the Integrated Annual Report including BRSR for the Financial Year 2025-26.
BSE8/13/2026
Settlement Agreement - Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosures Requirements) Regulations, 2015
Settlement Agreement - Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015
BSE8/11/2026
Investor Presentation
Investor Presentation - Q1 FY 26-27
BSE7/31/2026
Press Release / Media Release
Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials
BSE7/28/2026

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.